SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) AND CORONAVIRUS DISEASE 2019 (COVID-19)

Introduction. SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic. It is a single-stranded, positive-sense RNA virus belonging to the Coronaviridae family. It is highly contagious and can be spread through contact with infected individuals or through contact with contaminated surfaces.The aim of the study. This study examines the virology of SARS-CoV-2, including its structure, transmission, and treatment options, the novel coronavirus responsible for the COVID-19 pandemic.Materials and methods. Collection of clinical data from available medical resources for patients with confirmed SARS-CoV-2 infection. The viral RNA sequencing data were taken and analyzed to determine the genetic diversity of SARS-CoV-2.Results. SARS-CoV-2 is a single-stranded, positive-sense RNA virus belonging to the Coronaviridae family. It’s composed of 4 structural proteins: the spike (S) protein, the envelope (E) protein, the membrane (M) protein, and the nucleocapsid (N) protein. The S protein is responsible for the virus’s ability to bind to and enter host cells, while the E protein helps the virus evade the host’s immune system. The M protein helps to stabilize the virus’s structure, and the N protein helps to package the virus’s genetic material. The virus is highly contagious and can be spread through contact with infected individuals or through contact with contaminated surfaces. It was found that SARS-CoV-2 is highly diverse, with multiple genetic variants circulating in different regions. Furthermore, the viral load of SARS-CoV-2 was found to be significantly higher in patients with severe symptoms compared to those with mild symptoms. These findings provided important insights into the virology of SARS-CoV-2 and helped in the development of effective treatments and vaccines.Treatment options are limited but include antiviral medications, vaccines and supportive care. Currently, there are several vaccines available for SARS-CoV-2, including the Pfizer-BioNTech vaccine (Germany, 95% efficacy), the Moderna vaccine (USA, 94.1% efficacy), the AstraZeneca vaccine (UK, 62-90% efficacy), the Johnson & Johnson vaccine (USA, 66% efficacy), the Sinovac vaccine (China, 50.4% efficacy), Sputnik V vaccine (Russia, 91.6% efficacy) and Covaxin (India, 81% efficacy). All of these vaccines have been approved for use in various countries, and have been shown to be effective in preventing severe illness and death from SARS-CoV-2.Conclusion. Using a combination of molecular and bioinformatics techniques, the study identified the genomic structure of SARS-CoV-2 and its similarities to other coronaviruses. The study also identified the key proteins involved in the virus’s replication and pathogenesis. Furthermore, the study identified potential targets for antiviral therapies and vaccines. The results of this study provide important insights into the virology of SARS-CoV-2 and will be useful for the development of effective treatments and vaccines. This study also provides important insights into the virology of SARS-CoV-2 and will be useful for the further development of ideal treatments and vaccines.